8-K: Theravance Biopharma Reports Strong Q3 Results and Explores Strategic Options

Theravance Biopharma announced strong third-quarter 2024 results, highlighted by record YUPELRI sales, and initiated a strategic review to enhance shareholder value.

Summary

• Theravance Biopharma reported its third-quarter 2024 financial results, showing a net loss of $12.7 million, impacted by a $1.6 million non-cash impairment charge.
• YUPELRI net sales reached an all-time high of $62.2 million, a 7% increase year-over-year and a 14% increase sequentially.
• Hospital doses of YUPELRI increased by 40% compared to the same quarter last year.
• The company's implied 35% share of YUPELRI net sales was $21.8 million.
• TRELEGY net sales were $789 million, up 17% year-over-year, with potential milestone payments of $25 million if 2024 sales reach ~$2.9 billion and $50 million if sales reach ~$3.2 billion.
• CYPRESS enrollment is progressing as expected, with completion targeted for mid-2025 and data anticipated six months later.
• A Strategic Review Committee has been formed to explore options to unlock shareholder value.
• The roles of Chair of the Board and CEO have been separated, with Susannah Gray appointed as Chair.
• The company expects full-year 2024 R&D expenses of $30 million to $36 million and SG&A expenses of $45 million to $55 million, excluding share-based compensation.
• The company expects full-year share-based compensation expenses of $18 million to $22 million.
• Cash, cash equivalents, and marketable securities totaled $91.4 million as of September 30, 2024.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The strong YUPELRI sales and TRELEGY performance are positive, but the net loss and strategic review introduce some uncertainty. The separation of the Chair and CEO roles is a positive governance move. Overall, the sentiment is cautiously optimistic.

Positives

• YUPELRI sales reached a record high, demonstrating strong commercial performance.
• Hospital sales of YUPELRI showed significant growth, indicating successful market penetration.
• TRELEGY sales are strong, with potential for substantial milestone payments.
• The formation of a Strategic Review Committee suggests a proactive approach to enhancing shareholder value.
• The separation of the Chair and CEO roles may improve corporate governance and operational focus.
• CYPRESS enrollment is progressing as planned, maintaining development timelines.
• The company has a solid cash position of $91.4 million.

Negatives

• The company reported a net loss of $12.7 million for the quarter.
• A non-cash impairment charge of $1.6 million was incurred on long-lived assets.
• Non-GAAP net loss from operations was $2.9 million, compared to a loss of $0.7 million in the same period last year.
• The company's cash position decreased from $102.4 million at the end of 2023 to $91.4 million.

Risks

• The strategic review process may not result in any transaction.
• There is no guarantee that the TRELEGY sales milestones will be achieved.
• The company is dependent on third parties for the commercialization of YUPELRI and the development of ampreloxetine.
• Clinical trial results may not be favorable, impacting regulatory approvals.
• The company faces risks related to intellectual property protection and enforcement.
• The company's future profitability is subject to various market and economic conditions.

Future Outlook

The company expects levels of both non-GAAP losses and cash burn in the second half of 2024 to be similar to the first half. They also anticipate potential milestone payments from TRELEGY sales and are focused on growing YUPELRI sales and completing the CYPRESS study.

Management Comments

• Rick Winningham, Theravance Biopharma CEO, stated that they achieved a strong quarter for YUPELRI demand and made progress on recent mix-related pricing headwinds.
• Rick Winningham also mentioned that they are pleased with the progress made in CYPRESS and reaffirmed their development timelines.
• Management believes the separation of the Chair and CEO roles will allow management to sharpen its focus on operational goals.

Industry Context

The announcement comes amid a competitive landscape for respiratory therapies, with Theravance Biopharma focusing on its niche in nebulized treatments for COPD and a novel therapy for MSA. The company's collaboration with Viatris is a key factor in the commercial success of YUPELRI, and the potential for milestone payments from TRELEGY highlights the value of its partnerships.

Comparison to Industry Standards

• YUPELRI's 7% year-over-year sales growth and 14% sequential growth are strong compared to some other respiratory drugs in the market, but it is important to note that YUPELRI is a niche product in the nebulized LAMA space.
• TRELEGY's 17% year-over-year sales growth is impressive, reflecting the success of GSK's triple therapy inhaler. Comparatively, other triple therapies like AstraZeneca's Breztri Aerosphere have also shown strong growth, indicating a trend towards triple therapy in COPD management.
• The company's R&D spending of $9.3 million is relatively low compared to larger pharmaceutical companies, but is appropriate for a company of its size and stage of development. Companies like Regeneron and Vertex spend significantly more on R&D, but they have a much larger pipeline of products.
• The company's cash position of $91.4 million is adequate for its current operations, but it may need to raise additional capital if it wants to accelerate its development programs or pursue acquisitions. Companies like BioMarin and Alnylam have significantly larger cash reserves, but they also have more advanced pipelines and higher operating expenses.

Management Changes

Corporate Governance

Legal Proceedings

• A settlement agreement was reached with Qilu Pharmaceutical regarding patent litigation for YUPELRI, granting Qilu a license to market a generic version of YUPELRI in the US starting April 23, 2039.
• Patent litigation remains pending against three other ANDA filers.

Related Party Transactions

• The company has a co-promotion agreement with Viatris for YUPELRI, with a 35% profit share for Theravance Biopharma.

Stakeholder Impact

• Shareholders may benefit from the strategic review and potential value-unlocking initiatives.
• Employees may experience changes due to the strategic review and management changes.
• Patients may benefit from the continued development of YUPELRI and ampreloxetine.
• Viatris, as a partner, is impacted by the performance of YUPELRI.
• Royalty Pharma is impacted by the performance of TRELEGY.

Next Steps

• The Strategic Review Committee will assess alternatives to unlock shareholder value.
• The company will continue to enroll patients in the CYPRESS study, with completion expected in mid-2025.
• The company will monitor TRELEGY sales to determine if milestone payments will be triggered.
• The company will continue to focus on growing YUPELRI sales and market share.

Key Dates

Keywords

Theravance Biopharma, YUPELRI, revefenacin, TRELEGY, ampreloxetine, COPD, MSA, nOH, Strategic Review, Shareholder Value, Financial Results, Clinical Trials, Milestone Payments